Advertisement
U.S. markets open in 4 hours 16 minutes
  • S&P Futures

    5,214.75
    0.00 (0.00%)
     
  • Dow Futures

    39,227.00
    +4.00 (+0.01%)
     
  • Nasdaq Futures

    18,230.75
    -0.75 (-0.00%)
     
  • Russell 2000 Futures

    2,045.40
    -4.40 (-0.21%)
     
  • Crude Oil

    82.80
    +0.08 (+0.10%)
     
  • Gold

    2,155.80
    -8.50 (-0.39%)
     
  • Silver

    25.09
    -0.17 (-0.69%)
     
  • EUR/USD

    1.0848
    -0.0028 (-0.26%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.42
    +0.09 (+0.63%)
     
  • GBP/USD

    1.2686
    -0.0042 (-0.33%)
     
  • USD/JPY

    150.4290
    +1.3310 (+0.89%)
     
  • Bitcoin USD

    63,014.32
    -4,680.91 (-6.91%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,717.58
    -4.97 (-0.06%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk

In a report published Monday, Morgan Stanley analyst Matthew Harrison downgraded the rating on Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) to Equal-weight, while raising the price target from $77 to $126. The analyst believes that the stock valuation is "stretch" and that there is higher execution risk on the company's pipeline, although Ultragenyx continues to be a leading orphan disease company.

"Our downgrade is not related to a change in our view of Ultragenyx's pipeline, but rather of the risk/reward on upcoming pipeline events relative to valuation," Harrison explained.

Although the management has been able to successfully derisk KRN23 with robust initial data on rickets, additional data is awaited by the year-end, with meaningful value already having been attributed to the drug. However, management has not been able to similarly derisk triheptanoin.

Despite the previous robust single center results for triheptanoin, the analyst believes that there could still be some clinical risk. On the other hand there is significant academic data to dispute the risk that "the molecule does not have therapeutic activity," according to the Morgan Stanley report.

The analyst expects peak sales of over $1.5 billion, while mentioning that "it is hard to ignore that there are some clinical risks, esp. in the context of heightened valuation."

M&A could prove to be a possible driver of upside to the stock, especially seeing the support offered by the recent Synageva Biopharma Corp (NASDAQ: GEVA) acquisition.

"While we have no knowledge of any transaction, we do understand that orphan assets are highly sought after and some companies have expressed a desire to increase their orphan exposure," analyst Harrison added.

Latest Ratings for RARE

Jul 2015

Morgan Stanley

Downgrades

Overweight

Equal-weight

Jul 2015

JMP Securities

Initiates Coverage on

Outperform

Jun 2015

Canaccord Genuity

Maintains

Buy

View More Analyst Ratings for RARE
View the Latest Analyst Ratings

See more from Benzinga

© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement